换一批Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
第一作者：
Xinhua,Xiao
第一单位：
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
作者：
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);动物(Animals);蒽类(Anthracenes);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);吖庚因类(Azepines);苯甲酰胺类(Benzamides);细胞系, 肿瘤(Cell Line, Tumor);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);女(雌)性(Female);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);人类(Humans);JNK丝裂原活化蛋白激酶类(JNK Mitogen-Activated Protein Kinases);男(雄)性(Male);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);分子靶向治疗(Molecular Targeted Therapy);肿瘤蛋白质类(Neoplasm Proteins);前体B细胞淋巴母细胞白血病淋巴瘤(Precursor B-Cell Lymphoblastic Leukemia-Lymphoma);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-myc(Proto-Oncogene Proteins c-myc);吡啶类(Pyridines);嘧啶类(Pyrimidines);RNA干扰(RNA Interference);RNA, 小分子干扰(RNA, Small Interfering);辐射嵌合体(Radiation Chimera);随机分配(Random Allocation);信号传导(Signal Transduction);三唑类(Triazoles)
DOI
10.1186/s13045-020-00912-3
PMID
32552902
发布时间
2021-06-23
- 浏览3
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
